RM-MET / Metabolic and incretin signalling
Pramlintide
Also known as: Pramlintide acetate · Amylin analog
Grade describes the published research on the molecule. It is not a quality score, a safety score, or a release state.
What this is
Pramlintide is a modified analog of human amylin. It is not interchangeable with cagrilintide, native amylin or a GLP-1 receptor agonist.
Evidence position
The U.S. label and randomized human trials support Grade A for the finished comparator.
What the record does not establish
Those records do not establish the identity, purity, concentration or microbiological quality of another presentation.
Sources
- 01SymlinPen prescribing informationDailyMed / U.S. National Library of Medicine
- Shows
- U.S. finished-product label
- Does not show
- Does not authenticate another source or form
- 02One-year randomized controlled pramlintide trialPubMed
- Shows
- Controlled human data for pramlintide used with insulin
- Does not show
- Protocol-specific clinical evidence, not material testing
External database index
LIVE DATABASE INDEX / SEPARATE FROM CURATED EVIDENCE
Records below come directly from public scientific databases. They help find relevant material, but do not affect the evidence grade until they are matched to the molecule and added to the curated source list.
PUBCHEM / IDENTITY
Pramlintide
- CID
- 70691388
- Formula
- C171H267N51O53S2
- Mass
- 3949
PUBMED / FOUND RECORDS
- Amylin: Pharmacology, Physiology, and Clinical Potential.Pharmacological reviews / 2015 JulPMID 26071095 / DOI 10.1124/pr.115.010629
- Insulin Resistance in Type 1 Diabetes: Pathophysiological, Clinical, and Therapeutic Relevance.Endocrine reviews / 2025 May 9PMID 39998445 / DOI 10.1210/endrev/bnae032
- Development of Cagrilintide, a Long-Acting Amylin Analogue.Journal of medicinal chemistry / 2021 Aug 12PMID 34288673 / DOI 10.1021/acs.jmedchem.1c00565
- Amylin, Another Important Neuroendocrine Hormone for the Treatment of Diabesity.International journal of molecular sciences / 2024 Jan 26PMID 38338796 / DOI 10.3390/ijms25031517
- Amylin analogs for the treatment of obesity without diabetes: present and future.Expert review of clinical pharmacology / 2024 Sep 30PMID 39317404 / DOI 10.1080/17512433.2024.2409403
CLINICALTRIALS.GOV / FOUND RECORDS
- Effect of Basal-Bolus Closed-Loop Co-Administration of Insulin and Pramlintide on Improving the Glycemic Control in Type 1 DiabetesCOMPLETED / PHASE2 / McGill UniversityNCT02814123 / DIRECT title MATCH: Pramlintide
- Glucagon Counterregulation in Type 1 DiabetesTERMINATED / NA / University of VirginiaNCT03547427 / DIRECT intervention MATCH: Pramlintide
- Demonstrate the Effects of Pramlintide on Weight Reduction in SchizophreniaCOMPLETED / PHASE4 / University of Texas Southwestern Medical CenterNCT00690235 / DIRECT intervention MATCH: Pramlintide
- Continuous Subcutaneous Infusion of Pramlintide and InsulinCOMPLETED / PHASE4 / Baylor College of MedicineNCT00291772 / DIRECT intervention MATCH: Pramlintide
- Insulin-plus-pramlintide Closed-loop Strategy to Regulate Glucose Levels Without Carbohydrate CountingCOMPLETED / PHASE2 / McGill UniversityNCT03800875 / DIRECT title MATCH: Pramlintide